Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate.
Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor
The “Orange Book”, more formally known as Approved Drug Products with Therapeutic Equivalence Evaluations, identifies U.S. Food and Drug Administration (FDA) approved drug products as.
The antibody-drug conjugates market is anticipated to surge as several pharma companies across the globe are thoroughly working toward the development and expansion to treat a wide array of
/PRNewswire/ DelveInsight s Antibody-drug Conjugates Market Insights report delivers an in-depth understanding of the ADCs and the antibody-drug conjugates.